# GILEAD SCIENCES, INC. (GILD) FY2026 Q1 P&L / Income Statement - Company: GILEAD SCIENCES, INC. (GILD) - Period: 2026-01-01 to 2026-03-31 - Filing: Q1 FY2026 10-Q, filed 2026-05-07, accession number 0000882095-26-000024 - Page: https://plicit.ai/financials/gild/fy2026-q1-income-statement - Chart image: https://plicit.ai/charts/gild-fy2026-q1-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2026-01-01 through 2026-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,960,000,000 US dollars - **Cost of goods sold**: 1,445,000,000 US dollars - **Gross profit (calculated)**: 5,515,000,000 US dollars - **Operating expenses (calculated)**: 2,929,000,000 US dollars - **Operating income**: 2,586,000,000 US dollars - **Other income (expense), net (calculated)**: negative 6,000,000 US dollars - **Income before income taxes**: 2,580,000,000 US dollars - **Income tax expense**: 559,000,000 US dollars - **Net income**: 2,021,000,000 US dollars - **Tecartus - UNITED STATES**: 30,000,000 US dollars - **Tecartus - Rest of World**: 8,000,000 US dollars - **Tecartus - Europe**: 37,000,000 US dollars - **Total Cell Therapy - UNITED STATES**: 150,000,000 US dollars - **Total Cell Therapy - Rest of World**: 74,000,000 US dollars - **Total Cell Therapy - Europe**: 183,000,000 US dollars - **Total HIV - UNITED STATES**: 4,004,000,000 US dollars - **Total HIV - Rest of World**: 419,000,000 US dollars - **Total HIV - Europe**: 607,000,000 US dollars - **Biktarvy - UNITED STATES**: 2,573,000,000 US dollars - **Biktarvy - Rest of World**: 352,000,000 US dollars - **Biktarvy - Europe**: 437,000,000 US dollars - **Descovy - UNITED STATES**: 761,000,000 US dollars - **Descovy - Rest of World**: 23,000,000 US dollars - **Descovy - Europe**: 23,000,000 US dollars - **Genvoya - UNITED STATES**: 215,000,000 US dollars - **Genvoya - Rest of World**: 16,000,000 US dollars - **Genvoya - Europe**: 33,000,000 US dollars - **Odefsey - UNITED STATES**: 153,000,000 US dollars - **Odefsey - Rest of World**: 9,000,000 US dollars - **Odefsey - Europe**: 59,000,000 US dollars - **Other HIV - UNITED STATES**: 36,000,000 US dollars - **Other HIV - Rest of World**: 9,000,000 US dollars - **Other HIV - Europe**: 27,000,000 US dollars - **Symtuza - Revenue share - UNITED STATES**: 107,000,000 US dollars - **Symtuza - Revenue share - Rest of World**: 3,000,000 US dollars - **Symtuza - Revenue share - Europe**: 28,000,000 US dollars - **Yeztugo - UNITED STATES**: 158,000,000 US dollars - **Yeztugo - Rest of World**: 7,000,000 US dollars - **Yeztugo - Europe**: 0 US dollars - **Total Liver Disease - UNITED STATES**: 362,000,000 US dollars - **Total Liver Disease - Rest of World**: 235,000,000 US dollars - **Total Liver Disease - Europe**: 170,000,000 US dollars - **Livdelzi - UNITED STATES**: 115,000,000 US dollars - **Livdelzi - Rest of World**: 0 US dollars - **Livdelzi - Europe**: 18,000,000 US dollars - **Other Liver Disease - UNITED STATES**: 15,000,000 US dollars - **Other Liver Disease - Rest of World**: 21,000,000 US dollars - **Other Liver Disease - Europe**: 78,000,000 US dollars - **Sofosbuvir/Velpatasvir - UNITED STATES**: 141,000,000 US dollars - **Sofosbuvir/Velpatasvir - Rest of World**: 82,000,000 US dollars - **Sofosbuvir/Velpatasvir - Europe**: 60,000,000 US dollars - **Vemlidy - UNITED STATES**: 91,000,000 US dollars - **Vemlidy - Rest of World**: 132,000,000 US dollars - **Vemlidy - Europe**: 13,000,000 US dollars - **Total Oncology - UNITED STATES**: 403,000,000 US dollars - **Total Oncology - Rest of World**: 129,000,000 US dollars - **Total Oncology - Europe**: 278,000,000 US dollars - **AmBisome - UNITED STATES**: 7,000,000 US dollars - **AmBisome - Rest of World**: 72,000,000 US dollars - **AmBisome - Europe**: 59,000,000 US dollars - **Other - UNITED STATES**: 39,000,000 US dollars - **Other - Rest of World**: 11,000,000 US dollars - **Other - Europe**: 8,000,000 US dollars - **Total Other - UNITED STATES**: 46,000,000 US dollars - **Total Other - Rest of World**: 83,000,000 US dollars - **Total Other - Europe**: 67,000,000 US dollars - **Yescarta - UNITED STATES**: 120,000,000 US dollars - **Yescarta - Rest of World**: 67,000,000 US dollars - **Yescarta - Europe**: 146,000,000 US dollars - **Royalty, contract and other revenues - UNITED STATES**: 0 US dollars - **Royalty, contract and other revenues - Rest of World**: 6,000,000 US dollars - **Royalty, contract and other revenues - Europe**: 8,000,000 US dollars - **Trodelvy - UNITED STATES**: 253,000,000 US dollars - **Trodelvy - Rest of World**: 54,000,000 US dollars - **Trodelvy - Europe**: 95,000,000 US dollars - **Veklury - UNITED STATES**: 112,000,000 US dollars - **Veklury - Rest of World**: 18,000,000 US dollars - **Veklury - Europe**: 14,000,000 US dollars - **Product sales - UNITED STATES**: 4,926,000,000 US dollars - **Product sales - Rest of World**: 883,000,000 US dollars - **Product sales - Europe**: 1,137,000,000 US dollars - **Selling, general and administrative expenses**: 1,451,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 107,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 1,372,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Revenue before reconciliation (calculated)**: 21,115,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 14,155,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. ## Chart details: Revenue by Product and Service (18 categories) - Page: https://plicit.ai/financials/gild/fy2026-q1-income-statement/revenue-by-product-and-service-18-categories - Chart image: https://plicit.ai/charts/gild-fy2026-q1-revenue-by-product-and-service-18-categories-sankey.png Income statement for 2026-01-01 through 2026-03-31. View: Product and service (18 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,960,000,000 US dollars - **Cost of goods sold**: 1,445,000,000 US dollars - **Gross profit (calculated)**: 5,515,000,000 US dollars - **Operating expenses (calculated)**: 2,929,000,000 US dollars - **Operating income**: 2,586,000,000 US dollars - **Other income (expense), net (calculated)**: negative 6,000,000 US dollars - **Income before income taxes**: 2,580,000,000 US dollars - **Income tax expense**: 559,000,000 US dollars - **Net income**: 2,021,000,000 US dollars - **Tecartus**: 75,000,000 US dollars - **Yescarta**: 332,000,000 US dollars - **Biktarvy**: 3,361,000,000 US dollars - **Descovy**: 807,000,000 US dollars - **Genvoya**: 264,000,000 US dollars - **Odefsey**: 221,000,000 US dollars - **Symtuza - Revenue share**: 138,000,000 US dollars - **Yeztugo**: 166,000,000 US dollars - **Other HIV**: 73,000,000 US dollars - **Livdelzi**: 133,000,000 US dollars - **Sofosbuvir/Velpatasvir**: 283,000,000 US dollars - **Vemlidy**: 237,000,000 US dollars - **Other Liver Disease**: 114,000,000 US dollars - **Trodelvy**: 402,000,000 US dollars - **AmBisome**: 138,000,000 US dollars - **Other**: 58,000,000 US dollars - **Royalty, contract and other revenues**: 14,000,000 US dollars - **Veklury**: 144,000,000 US dollars - **Selling, general and administrative expenses**: 1,451,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 107,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 1,372,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (2 categories) - Page: https://plicit.ai/financials/gild/fy2026-q1-income-statement/revenue-by-product-and-service-2-categories - Chart image: https://plicit.ai/charts/gild-fy2026-q1-revenue-by-product-and-service-2-categories-sankey.png Income statement for 2026-01-01 through 2026-03-31. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,960,000,000 US dollars - **Cost of goods sold**: 1,445,000,000 US dollars - **Gross profit (calculated)**: 5,515,000,000 US dollars - **Operating expenses (calculated)**: 2,929,000,000 US dollars - **Operating income**: 2,586,000,000 US dollars - **Other income (expense), net (calculated)**: negative 6,000,000 US dollars - **Income before income taxes**: 2,580,000,000 US dollars - **Income tax expense**: 559,000,000 US dollars - **Net income**: 2,021,000,000 US dollars - **Product sales**: 6,946,000,000 US dollars - **Royalty, contract and other revenues**: 14,000,000 US dollars - **Selling, general and administrative expenses**: 1,451,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 107,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 1,372,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/gild/fy2026-q1-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/gild-fy2026-q1-revenue-by-geography-sankey.png Income statement for 2026-01-01 through 2026-03-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,960,000,000 US dollars - **Cost of goods sold**: 1,445,000,000 US dollars - **Gross profit (calculated)**: 5,515,000,000 US dollars - **Operating expenses (calculated)**: 2,929,000,000 US dollars - **Operating income**: 2,586,000,000 US dollars - **Other income (expense), net (calculated)**: negative 6,000,000 US dollars - **Income before income taxes**: 2,580,000,000 US dollars - **Income tax expense**: 559,000,000 US dollars - **Net income**: 2,021,000,000 US dollars - **UNITED STATES**: 4,926,000,000 US dollars - **Europe**: 1,144,000,000 US dollars - **Rest of World**: 889,000,000 US dollars - **Undisclosed (calculated)**: 1,000,000 US dollars - **Selling, general and administrative expenses**: 1,451,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Acquired in-process research and development expenses**: 107,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 1,372,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.